Discussing Low-Grade Serous Ovarian Carcinoma (LGSOC) with a specific focus on VS-6766 and trametinib

Executed on:Apr 8, 2022 11:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: MD Anderson

Professor of Gynecologic Oncology at MD Anderson & Co-Principal Investigator of M.D. Anderson’s NCI-funded SPORE in Ovarian Cancer.
Research is focused on ovarian cancer, particularly translational studies of rare ovarian tumors: low-grade serous tumors (serous tumors of low malignant potential and low-grade serous carcinomas), clear cell carcinomas, mucinous carcinomas, malignant ovarian germ cell tumors, and sex cord-stromal ovarian tumors. 
Principal investigator or co-principal investigator of clinical trials focused on novel therapeutics for patients with low-grade serous carcinoma of the ovary and has served as a member of the NCI’s Gynecologic Cancer Steering Committee, which approves all new phase III and randomized phase II clinical trials for gynecologic cancers in North America.

Interview Goal

This conversation will focus on the patient population for Low-Grade Serous Ovarian Carcinoma (LGSOC) and the potential of Verastem's VS-6766

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.